SARS-CoV-2 has ushered a global pandemic with no effective drug being available at present. Although several FDA-approved drugs are currently under clinical trials for drug repositioning, there is an on-going global effort for new drug identification. In this paper, using multi-omics (interactome, proteome, transcriptome, and bibliome) data and subsequent integrated analysis, we present the biological events associated with SARS-CoV-2 infection and identify several candidate drugs against this viral disease. We found that: (i) Interactome-based infection pathways differ from the other three omics-based profiles. (ii) Viral process, mRNA splicing, cytokine and interferon signaling, and ubiquitin mediated proteolysis are important pathways in SARS-CoV-2 infection. (iii) SARS-CoV-2 infection also shares pathways with Influenza A, Epstein-Barr virus, HTLV-I, Measles, and Hepatitis virus. (iv) Further, bacterial, parasitic, and protozoan infection pathways such as Tuberculosis, Malaria, and Leishmaniasis are also shared by this virus. (v) A total of 50 candidate drugs including the prophylaxis agents and pathway specific inhibitors are identified against COVID-19. (vi) Betamethasone, Estrogen, Simvastatin, Hydrocortisone, Tositumomab, Cyclosporin A etc. are among the important drugs. (vii) Ozone, Nitric oxide, and photosensitizer drugs are also identified as possible therapeutic candidates. (viii) Curcumin, Retinoic acids, Vitamin D, Arsenic, Copper, and Zinc may be the candidate prophylaxis agents. Nearly 70% of our identified agents are previously suggested to have anti-COVID-19 effects or under clinical trials. Among our identified drugs, the ones that are not yet tested, need validation with caution while an appropriate drug combination from these candidate drugs along with a SARS-CoV-2 specific antiviral agent is needed for effective COVID-19 management.

SARS-CoV-2 已引发全球大流行，目前尚无有效药物。尽管 FDA 批准的几种药物目前正在进行药物重新定位的临床试验，但全球仍在努力进行新药鉴定。在本文中，我们利用多组学（相互作用组、蛋白质组、转录组和文献组）数据和随后的综合分析，提出了与 SARS-CoV-2 感染相关的生物学事件，并确定了几种针对这种病毒性疾病的候选药物。我们发现：（i）基于相互作用组的感染途径与其他三个基于组学的特征不同。(ii) 病毒过程、mRNA 剪接、细胞因子和干扰素信号转导以及泛素介导的蛋白水解是 SARS-CoV-2 感染的重要途径。(iii) SARS-CoV-2 感染还与甲型流感、Epstein-Barr 病毒、HTLV-I、麻疹和肝炎病毒共享途径。(iv) 此外，该病毒还具有细菌、寄生虫和原生动物感染途径，例如结核病、疟疾和利什曼病。(v) 总共确定了 50 种针对 COVID-19 的候选药物，包括预防药物和途径特异性抑制剂。（六）重要药物有倍他米松、雌激素、辛伐他汀、氢化可的松、托西莫单抗、环孢素A等。(vii) 臭氧、一氧化氮和光敏剂药物也被确定为可能的治疗候选药物。(viii) 姜黄素、视黄酸、维生素 D、砷、铜和锌可能是候选预防剂。我们已确定的药物中，近 70% 之前被认为具有抗 COVID-19 作用或正在进行临床试验。在我们确定的药物中，尚未测试的药物需要谨慎验证，而有效的 COVID-19 管理需要这些候选药物与 SARS-CoV-2 特异性抗病毒药物的适当药物组合。